M

Magenta Therapeutics Inc
F:3MT

Watchlist Manager
Magenta Therapeutics Inc
F:3MT
Watchlist
Price: 11.136 EUR 0.29% Market Closed
Market Cap: 368.6m EUR

Relative Value

There is not enough data to reliably calculate the relative value of 3MT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

3MT Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.8
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-4.6
Industry
24.1
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-5.7
Industry
21.8
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-5.7
Industry
23.8
vs History
vs Industry
Median 3Y
5.3
Median 5Y
0.3
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-4
Median 5Y
-3.8
Industry
6.3
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-3.7
Industry
6.7
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.7
Industry
7.9
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-4.6
Industry
6.3
vs History
vs Industry
Median 3Y
1 380.5
Median 5Y
-12.7
Industry
5.5

Multiples Across Competitors

3MT Competitors Multiples
Magenta Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Magenta Therapeutics Inc
F:3MT
368.6m EUR 0 -5.7 -4.4 -4.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 623 419.7 -159 807.1 -194 056.8 -191 842.4
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.2 -534.6 -582.2 -566.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.6B USD 16.4 1 207.3 162.8 197.4
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.3 59.9
P/S Multiple
Revenue Growth P/S to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average P/S: 3 362 558.2
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 623 419.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.4
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 095.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
US
M
Magenta Therapeutics Inc
F:3MT
Average P/E: 191
Negative Multiple: -5.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 807.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 207.3
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average EV/EBITDA: 40.3
Negative Multiple: -4.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 056.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.8
N/A N/A
NL
argenx SE
XBRU:ARGX
58.3
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Magenta Therapeutics Inc
F:3MT
Average EV/EBIT: 46.5
Negative Multiple: -4.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 842.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.4
N/A N/A
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A